Provigil rejected for ADHD

An FDA advisory panel has recommended rejecting Cephalon's application to market Sparlon, a clone of its narcolepsy drug Provigil, for ADHD in children. "The advisory committee voted 12-to-1 against recommending Sparlon's approval, citing its concerns about Stevens-Johnson syndrome, a rare and vicious blistering of the skin that can be caused by certain drugs."